Nephros Announces Launch of PluraPath™, a Real-Time, Portable, Water Pathogen Detection System
January 09 2020 - 7:30AM
via NEWMEDIAWIRE -- Nephros, Inc. (Nasdaq: NEPH), a
commercial-stage company that develops and sells high performance
water purification products and pathogen detection systems to the
medical device and commercial markets, today announced that it has
formally launched PluraPathTM, the only commercially available
portable water pathogen detection system designed to provide
actionable data for infection control teams on up to 15 different
pathogens from a single water sample, in approximately one
hour.
“In recognition of the large market need and
opportunity, we are excited to launch our real-time, portable water
pathogen detection system – PluraPathTM,” said Daron Evans,
President and CEO of Nephros. “Often finding ourselves present
during pathogen outbreaks, we recognized the need for faster,
actionable data. Every hour of delay increases patient risk.
Additionally, solely focusing on legionella misses additional
pathogens that can contribute to making patients sick. Our
PluraPathTM system evaluates up to 15 separate pathogens, including
legionella, pseudomonas, shigella, salmonella, mycobacterium, E.
coli., norovirus and other potentially dangerous bacterial and
viral pathogens.”
“Initially, we will be working with our
strategic distributors to provide capability demonstrations to
medical facilities across the country. The combination of rational,
regimented pathogen testing, actively managed water disinfection
programs, and the risk-based placement of point-of-use filtration
provides enhanced protection for patients from the risks and
illnesses associated with waterborne pathogens.”
The PluraPathTM system uses quantitative
polymerase chain reaction (qPCR) technology to provide estimated
colony forming units per milliliter (CFU/ml) information to
infection control teams on a real-time basis. Each assay has been
developed to target specific DNA or RNA segments of the target
pathogens. The system leverages Nephros’s proprietary
ultrafiltration technology to concentrate the water sample and to
decrease the lower limit of detection of pathogens in a 1 liter
water sample.
Nephros expects real-time data from the
PluraPathTM to enable infection control teams to quickly assess
potential risks throughout a medical facility, allowing teams to
dynamically deploy resources and disinfection efforts during water
pathogen outbreaks. Additionally, when used in conjunction with
gold-standard lab-based testing methodologies, PluraPathTM can
support the routine testing prescribed by each facility’s water
management plan.
“We are pleased at the performance of our system
to detect the presence of pathogens as low as 10 CFU/ml,” said Dr.
Kimothy Smith, Vice President of Pathogen Diagnostic Products.
“Combined with our unique sample preparation step, we can identify
pathogen levels that are below standard action levels for potable
water. PluraPath™ will enable our customers to evaluate and monitor
the ‘biome’ of their building’s water systems in a way not
currently available without significantly greater time and expense.
We look forward to working with our authorized Nephros ultrafilter
distributors to integrate the PluraPathTM system into their
customers’ water management plan activities.”
More information, including a white paper about
the Nephros PluraPathTM system can be found at
www.nephros.com/pathogen. Please contact your authorized
Nephros distributor to schedule an informational webinar or an
on-site demonstration of the Nephros PluraPathTM system.
About Nephros, Inc.
Nephros is a commercial stage company that
develops and sells high performance water purification products and
pathogen detection systems to the medical device and commercial
markets. Nephros ultrafilters and pathogen detection systems are
used in hospitals and medical clinics to assess and reduce the
infection risks from waterborne pathogens (e.g., Legionella,
Pseudomonas) in showers, sinks, and ice machines. Additionally,
Nephros ultrafilters are used by dialysis centers for assisting in
the added removal of endotoxins and other biological contaminants
from the water and bicarbonate concentrate supplied to hemodialysis
machines and patients.
Nephros filters, including AETHER™ brand
filters, improve the taste and odor of water and reduce biofilm,
bacteria, and scale build-up in downstream equipment. Nephros and
AETHER™ products are used in the health care, food service,
hospitality, and convenience store markets.
For more information about Nephros, please visit
the company’s website at www.nephros.com.
Forward-Looking Statements
This release contains forward-looking statements
that are subject to various risks and uncertainties. Such
statements include statements regarding the PluraPath™ system
capabilities, marketability and sensitivities; and other statements
that are not historical facts, including statements which may be
accompanied by the words “intends,” “may,” “will,” “plans,”
“expects,” “anticipates,” “projects,” “predicts,” “estimates,”
“aims,” “believes,” “hopes,” “potential” or similar words. Actual
results could differ materially from those described in these
forward-looking statements due to certain factors, including
changes in business, economic and competitive conditions, lack of
acceptance of the PluraPathTM system or other delays in a wide
rollout of the system, and the availability of financing or other
capital when needed. These and other risks and uncertainties are
detailed in Nephros’s reports filed with the U.S. Securities and
Exchange Commission, including its Annual Report on Form 10-K for
the year ended December 31, 2018. Nephros does not undertake any
responsibility to update the forward-looking statements in this
release.
Contact:
Investor Relations Contacts:
Kirin Smith, President
PCG Advisory, Inc.
(646) 863-6519
ksmith@pcgadvisory.com
Andy Astor, COO & CFO
Nephros, Inc.
(201) 345-0824
andy@nephros.com
Nephros (NASDAQ:NEPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nephros (NASDAQ:NEPH)
Historical Stock Chart
From Apr 2023 to Apr 2024